Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keeping Track: Pre-Independence Day Fireworks Crackle At US FDA With Burst Of Approvals And Filings

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker.


Related Content

Gottlieb: Epidiolex Approval Covers One Specific Cannabidiol Medication, Not Marijuana
Epidiolex Advisory Committee Appears To Be Covering US FDA's Bases, But Liver Injury Concerns Persist
Flu Vaccine Strains Get Easy OK From FDA Panel, But Desire For More Efficacy Remains
Not Out Of The Dark Yet: UK’s NICE Turns Down Clinuvel’s Phototoxicity Drug Scenesse
Pfizer's Oncology Strategy Centers On Three Anchors To Steady The Ship
Keeping Track: Merck's Winning Week; Novel Agents Submitted By GSK, Melinta, Portola
Keeping Track: Approvals For Genentech And AstraZeneca, CR Letter For Neos, And Breakthrough For Teva
Scenesse Approval Buoys Clinuvel As It Fights Retrophin
FDA blesses combo use of GSK's Mekinist, Tafinlar in melanoma
Tandem Approval Brings GSK’s Tafinlar And Mekinist To A Market Ready To Test Combinations


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts